Literature DB >> 16127020

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

Radjesh J Bisoendial, G Kees Hovingh, Karim El Harchaoui, Johannes H M Levels, Sotirios Tsimikas, Kewei Pu, Aeilko E Zwinderman, Jan Albert Kuivenhoven, John J P Kastelein, Erik S G Stroes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127020     DOI： 10.1161/01.ATV.0000179009.60612.28

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  7 in total

1.  Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Authors:  Guoqing Cao; Thomas P Beyer; Youyan Zhang; Robert J Schmidt; Yan Q Chen; Sandra L Cockerham; Karen M Zimmerman; Sotirios K Karathanasis; Ellen A Cannady; Todd Fields; Nathan B Mantlo
Journal:  J Lipid Res       Date:  2011-09-25       Impact factor: 5.922

Review 2.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

3.  Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD).

Authors:  Madeleine V Pahl; Zhenmin Ni; Lili Sepassi; Hamid Moradi; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

4.  Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Authors:  Eric J Niesor; David Kallend; Darren Bentley; John J P Kastelein; G Kees Hovingh; Erik S G Stroes
Journal:  Lipids       Date:  2014-10-04       Impact factor: 1.880

5.  Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

Authors:  Tetsuro Miyazaki; Kazunori Shimada; Katsumi Miyauchi; Atsumi Kume; Kosei Tanimoto; Takashi Kiyanagi; Katsuhiko Sumiyoshi; Makoto Hiki; Hiroshi Mokuno; Shinya Okazaki; Hitoshi Sato; Takeshi Kurata; Hiroyuki Daida
Journal:  Lipids Health Dis       Date:  2010-10-25       Impact factor: 3.876

Review 6.  Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.

Authors:  Chuanwei Li; Wen Zhang; Faying Zhou; Caiyu Chen; Liang Zhou; Yafei Li; Ling Liu; Fang Pei; Hao Luo; Zhangxue Hu; Jing Cai; Chunyu Zeng
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

7.  High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity.

Authors:  Sandrine Chantepie; Andrea E Bochem; M John Chapman; G Kees Hovingh; Anatol Kontush
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.